Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A new antibody-drug conjugate (ADC) is stepping into the spotlight. The FDA has granted fast track designation to SBE303, a Nectin-4–targeting ADC developed by Samsung Bioepis, for patients with locally advanced or metastatic urothelial cancer who previously received enfortumab vedotin. An ongoing phase 1 trial is now enrolling patients to assess its safety and early efficacy.
A new contender in bladder cancer treatment just got a regulatory boost. The FDA has granted fast track designation to SBE303, Samsung Bioepis's first antibody-drug conjugate (ADC), for patients with locally advanced or metastatic urothelial cancer who have already been treated with enfortumab vedotin (Padcev). The designation reflects the significant unmet need in this pretreated population, where options remain limited.
SBE303 works by targeting Nectin-4 — a protein overexpressed on several tumor types including urothelial, lung, and breast cancers. Once bound, the drug is internalized and releases a topoisomerase I inhibitor payload that kills the cancer cell. Early nonclinical data showed meaningful tumor growth inhibition in Nectin-4–positive models, and the drug appeared well-tolerated in animal studies with no severe systemic toxicity.
Key Takeaways:
Why it matters: Urothelial cancer patients who progress after enfortumab vedotin have very few treatment options. SBE303's fast track status could accelerate its path through clinical development, potentially offering a next-generation ADC option for a population in urgent need.
